Overview

• FMBA chief Veronika Skvortsova announced at the Eastern Economic Forum that Enteromix completed required preclinical studies and is ready to move into human testing.
• Developers say documents have been submitted to the Health Ministry, with an initial Phase I trial reported to involve up to 48 participants.
• Enteromix is a personalized mRNA immunotherapy that uses AI to select neoantigens, with colorectal cancer as the first target and candidates for glioblastoma and certain melanomas advancing.
• Preclinical work reportedly showed safety after repeated dosing and tumor shrinkage or slower progression in about 60–80% of cases, alongside improved survival in test models.
• Some outlets touted 100% efficacy and imminent rollout, but those claims conflict with official figures and there are no peer‑reviewed data or regulatory approvals yet.